Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Teva

Teva and FP Movement collaborate on limited edition women’s sandals & hiking boots

Teva‘s Grandview GTX hiking boot and quick-drying Terra Fi 5 sandal get stylish makeovers

Advnture

Best sandals for men to wear this summer

Let us introduce you to your new season footwear rotation

Evening Standard

Teva Pharmaceuticals Stock Has Unusual Call Options Activity After Its Q1 Results

Teva Pharmaceuticals, the generic drug maker, posted good Q1 results today, reaffirming its forecast for significant free cash flow in 2024. That led to unusual call options activity based on a Barchart report.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Teva Pharma's Turnaround Story: How A Key Win Helped It Clinch A Five-Year High

Teva stock surged Wednesday after the company beat first-quarter views and unveiled promising results from its schizophrenia drug study.

Investors Business Daily

A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation

As the earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation are due to report.

Investors Business Daily

3 Biotech Stocks to Watch for Lucrative Gains

The biotech sector’s robust long-term growth is driven by strong government support, the rising foothold of personalized medicine, the growing number of orphan drug formulations, and rapid AI adoption. Hence, biotech stocks G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), and Royalty Pharma (RPRX) could be ideal additions to your watchlist. Keep…

StockNews.com

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Roll Call

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

StockNews.com

5 Pharma Stocks to Watch With Bullish Momentum

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

StockNews.com

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

3 Smart Pharma Picks Serving Gains

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

StockNews.com

Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short.

Teva stock neared a profit-taking zone Wednesday, while GSK stock bounded briefly out of a chase zone on strong fourth-quarter performances for both.

Investors Business Daily

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

Investors Business Daily

Dow Jones Ends Winning Streak; Cathie Wood Stock Soars On Earnings

Dow Jones pared losses in the afternoon. Cathie Wood's holding, RBLX soared while chip new issue ARM fell ahead of earnings.

Investors Business Daily

Teva Pharma Makes A Bullish Move After Quarterly Beat, Business Separation Plans

Teva stock made inroads toward its 50-day line on Wednesday after the pharma giant rode its generics drugs business to a third-quarter beat.

Investors Business Daily

Trendy Hoka Shoes Maker Breaks Out On Earnings As Year's Gain Hits 47%

Deckers Outdoor is up 47% so far this year. It plans a strategic shift.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

StockNews.com

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

StockNews.com

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

The Independent UK

Teva to pay $225M to settle cholesterol drug price-fixing charges

The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of a widely used cholesterol-lowering drug

StockNews.com

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

Investors Business Daily

Teva Retakes Its 200-Day Line After Second-Quarter Beat And Raise

Teva stock retook its 200-day moving average early Wednesday after the generic drugs giant beat second-quarter estimates.

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Steve Reitmeister

501 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.